Press release
Comprehensive 2025 Primary Biliary Cholangitis Market Overview: Trends, Forecasts, and Growth Drivers
Primary Biliary Cholangitis
What Is the Expected CAGR for the Primary Biliary Cholangitis Market Through 2025?
The market size for primary biliary cholangitis has experienced a swift expansion in the past few years. It is projected to escalate from $0.98 billion in 2024 to $1.09 billion in 2025, yielding a compound annual growth rate (CAGR) of 11.8%. This growth in the historic period is attributed to enhanced disease awareness, increased worldwide health care expenditure, strategic alliances in the healthcare industry, emphasis on patient advocacy, and government measures for liver health.
What's the Projected Size of the Global Primary Biliary Cholangitis Market by 2029?
In the coming years, the market size for primary biliary cholangitis is expected to experience robust growth. Projections show it reaching $1.6 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.9%. The growth witnessed during the prediction period can be associated with the enhancement of biomarker studies, worldwide efforts in managing rare diseases, an upsurge in collaborations in clinical trials, and a patient-centric approach to healthcare, along with an increasing demand for liver transplants. Key trends for the prediction period encompass progression in biomarker research, an intensified concentration on non-invasive diagnostic methods, a research emphasis on immunomodulatory therapies, incorporation of Artificial Intelligence (AI), patient-reported feedback in clinical trials, utilization of telemedicine for patient management, a focus on combination therapies, and newly emerging therapies targeting fibrosis.
View the full report here:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Top Growth Drivers in the Primary Biliary Cholangitis Industry: What's Accelerating the Market?
The primary biliary cholangitis market is anticipated to grow due to the rising trend in smoking. The act of smoke inhalation and exhalation from burning tobacco or other substances is what constitutes smoking, a notable risk factor for liver diseases, inclusive of PBC. Heightened smoking rates translate to an increase in individuals seeking medical intervention for liver-related complications. In particular, cigarette production in Canada saw a 2.2% increase in July 2023 compared to June 2023, as reported by Statistics Canada, a government agency based in the country. Furthermore, there was a 2.6% upturn in cigarette sales in June, culminating at 1.4 billion units relative to May. Hence, the rise in smoking rate is expected to stimulate the growth of the primary biliary cholangitis market. The primary biliary cholangitis market is poised to experience further expansion due to the escalation in liver cancer instances. Liver cancer commences in the liver cells and has varying types, including cholangiocarcinoma and hepatocellular carcinoma, all of which amplify the importance of primary biliary cholangitis in cancer-related complications. The gradual increase in the prevalence of this disease and its possible negative repercussions add to the growth of the primary biliary cholangitis market. The American Cancer Society, a prominent professional organization in the U.S, in January 2024, projected that the country would register approximately 41,630 new liver cancer cases, with 28,000 from men and 13,630 from women. Furthermore, an estimated 29,840 individuals (19,120 men and 10,720 women) are anticipated to lose their lives to this disease. Consequently, the increase in liver cancer cases is accelerating the growth of the primary biliary cholangitis market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
What Trends Will Shape the Primary Biliary Cholangitis Market Through 2029 and Beyond?
Businesses in the primary biliary cholangitis market are concentrating their efforts on creating unique and advanced treatments like orphan drugs, which blend obeticholic acid (OCA) and bezafibrates, as a strategy to achieve exclusive control of the market. The goal behind combining OCA and bezafibrate with an orphan drug designation is to provide a more thorough and efficient treatment plan for primary biliary cholangitis (PBC), potentially enhancing the life quality for those living with this uncommon disease. For example, in May 2023, US-based biopharmaceutical firm Intercept Pharmaceuticals, Inc. received FDA approval for an orphan drug designation for the mix of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a potential treatment for PBC, a progressive liver ailment, and obeticholic acid (sold under the name Ocaliva) is US-approved treatment for PBC.
What Are the Main Segments in the Primary Biliary Cholangitis Market?
The primary biliary cholangitis market covered in this report is segmented -
1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp
Which Top Companies are Driving Growth in the Primary Biliary Cholangitis Market?
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.
Which Regions Will Dominate the Primary Biliary Cholangitis Market Through 2029?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520
"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Comprehensive 2025 Primary Biliary Cholangitis Market Overview: Trends, Forecasts, and Growth Drivers here
News-ID: 4126393 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
